Modality
Gene Therapy
MOA
AuroraAi
Target
PSMA
Pathway
T-cell
ThymomaGASchizophrenia
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
Nov 2020
→ Jan 2030
Phase 1Current
NCT08071160
2,717 pts·Thymoma
2022-07→2029-09·Not yet recruiting
NCT03618189
2,396 pts·GA
2020-11→2030-01·Active
5,113 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-09-263.5y awayInterim· Thymoma
2030-01-113.8y awayInterim· GA
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P1
Active
P1
Not yet…
Catalysts
Interim
2029-09-26 · 3.5y away
Thymoma
Interim
2030-01-11 · 3.8y away
GA
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08071160 | Phase 1 | Thymoma | Not yet recr... | 2717 | 6MWD |
| NCT03618189 | Phase 1 | GA | Active | 2396 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BII-1564 | Biogen | Phase 2 | PSMA |